


QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally



The global clinical laboratory services market has reached nearly [\\$225 billion](#), fueled in large part by growing demand for esoteric testing, especially genetic and genomic testing. Meeting this growing demand are specialized diagnostic laboratories offering a wide array of diagnostic tests to providers around the world.

Based in Edison, NJ, QDx Pathology Services (“QDx”) is a national, independent, full-service molecular and anatomical pathology laboratory dedicated to providing diagnostic excellence to the company’s customers and their patients. The company’s CLIA and CAP certified laboratory utilizes the latest in state-of-the-art instrumentation and information technology.

QDx’s broad array of testing capabilities, established client base and payor coverage and U.S. footprint made it the ideal partner for South Korea-based LabGenomics to expand its business into the fast-growing U.S. market.

Crosstree’s unique knowledge of the global diagnostic laboratory market and current trends helped QDx identify LabGenomics as the ideal strategic fit. The resulting collaboration will enable the combined company to accelerate growth, significantly expand its service offerings, and increase its reach globally.

Crosstree's unique knowledge of the global diagnostic testing industry generates innovative outcomes.

ABOUT QDX PATHOLOGY



QDx Pathology Services is a privately-held, CLIA-certified facility located in Central New Jersey, serving medical professionals throughout the country. Its mission is to deliver diagnostic excellence and accuracy for every patient utilizing the latest, state-of-the-art instrumentation and medical technology. QDx offers healthcare providers direct access to its highly experienced, board-certified pathology staff which averages 15 years of experience.

A portfolio company of Hadley Capital.

ABOUT LABGENOMICS



LabGenomics is a healthcare company specializing in molecular diagnostics, dedicated to the development of new and effective diagnostics methods for various diseases. Founded in 2002, the company has concentrated on the molecular diagnostics market and now serves more than 3,000 hospitals and clinics across South Korea.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JEFF ELLIS

Co-Founder & Managing Director

jeff.ellis@crosstreecapital.com

813-774-4753